FDA Approves Subcutaneous Infliximab for IBD FDA Approves Subcutaneous Infliximab for IBD
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn ' s disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news
More News: Crohn's Disease | Gastroenterology | Health | Inflammatory Bowel Disease | Remicade | Ulcerative Colitis